Renal effects of continuous infusion of recombinant interleukin-2 in children
- 1 January 1991
- journal article
- research article
- Published by Springer Nature in Pediatric Nephrology
- Vol. 5 (1) , 33-37
- https://doi.org/10.1007/bf00852838
Abstract
Recombinant interleukin-2 (rIL-2) is a new promising treatment for cancer, but is associated with severe renal toxicity. This study is the first to analyse the renal effects of rIL-2 in children. Twenty-one cycles of continuous rIL-2 infusion were studied in 15 patients; mean age was 6.9 years and average weight 18.9 kg. Interstitial fluid retention and oliguria (baseline, 1.7 ml/kg per hour; nadir, 0.5 mg/kg per hour) were associated with hypotension (baseline, 101/56 mm Hg; nadir, 85/43 mm Hg) and decreased intravascular volume (plasma renin activity increased×10). Weight gain (+7.9%) was observed in 13 cycles whereas weight loss (−6.3%) was shown in 8 cycles because of digestive and cutaneous losses, mainly in the youngest patients. This prerenal azotaemia was characterized by a decrease in creatinine clearance (from 101 to 36 ml/min per 1.73 m2) and a low fractional excretion and sodium (FENa) (from 0.70% to 0.09%).Hypotension and hypovolaemia needed vascular filling (n=12), dopamine (n=7) and interruption of rIL-2 (n=2). Most abnormalities occurred as early as day 2 of therapy and were always reversible after a short period with sodium leakage (diuresis=2.2 ml/kg per hour, FENa=2.01%). Hypophosphataemia was associated with low urinary excretion of phosphorus, suggesting an increased uptake of inorganic phosphorus by rapidly proliferating lymphoid cells.Keywords
This publication has 14 references indexed in Scilit:
- Nephrotic Syndrome Associated with Recombinant Interleukin-2Nephron, 1990
- A phase-II study of adoptive immunotherapy with continuous infusion of interleukin-2 in children with advanced neuroblastoma. A report on 11 casesCancer Treatment Reviews, 1989
- Clinical immunotherapy studies in the surgery branch of the U.S. National Cancer Institute: brief reviewCancer Treatment Reviews, 1989
- Interleukin-2 Initiates Metabolic Responses Associated with Critical Illness in HumansAnnals of Surgery, 1988
- Clinical Implications of Prostaglandin and Thromboxane A2FormationNew England Journal of Medicine, 1988
- Inhibition of Cyclo-oxygenase Attenuates the Metabolic Response to Endotoxin in HumansArchives of Surgery, 1988
- A Progress Report on the Treatment of 157 Patients with Advanced Cancer Using Lymphokine-Activated Killer Cells and Interleukin-2 or High-Dose Interleukin-2 AloneNew England Journal of Medicine, 1987
- Constant-Infusion Recombinant Interleukin-2 in Adoptive Immunotherapy of Advanced CancerNew England Journal of Medicine, 1987
- Renal Physiology of the Prostaglandins and the Effects of Nonsteroidal Anti-Inflammatory Agents on the KidneyAmerican Journal of Nephrology, 1987
- Observations on the Systemic Administration of Autologous Lymphokine-Activated Killer Cells and Recombinant Interleukin-2 to Patients with Metastatic CancerNew England Journal of Medicine, 1985